Abstract
Alzheimer’s disease is a progressive neurodegenerative disorder, which is characterized by amyloid β peptide deposition in the brain. Aβ peptide, the major component of amyloid plaques is generated by the sequential processing of a larger protein called amyloid Precursor Protein by β-amyloid cleaving enzyme (BACE-1). In this study, we appllied computer assisted methodology unifying molecular docking and pharmacophore filtering to identify potent inhibitors against BACE-1. In order to inspect the pharmacophore region and binding mode of BACE-1 135 reported co-crystallized ligands of BACE-1 were docked into the active site using Glide XP. The present molecular docking studies provided critical information on protein ligand interactions that revealed imminent information on chemical features essential to inhibiting BACE-1. Based on the docking results we proposed structure based pharmacophore features that hold well as potent BACE-1 inhibitors. A huge set of compounds was docked into the active site of BACE-1 and the hits from the docking were filtered to match the chemical features of the pharmacophore model. The compounds resulting from the pharmacophore filtering were again re-docked into the active site of BACE-1 and the three hits bound well into the active sites and matched the pharmacophore models which were identified as possible potential inhibitors of BACE-1. Molecular dynamics simulation reveals that lead 3 shows constant RMSD and the number of hydrogen bonding with the protein among the identified three lead molecules.
Similar content being viewed by others
References
Barrow, J.C., McGaughey, G.B., Nantermet, P.G., Rajapakse, H.A., Selnick, H.G., Stauffer, S.R., Coburn, C.A. 2005. 1,3,5-Substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer’s disease. WO/2005/103020. http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005103020&recNum=89&docAn=US2005012973&queryString=(FP/beta-secretase)%2520&maxRec=161.
Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H. 2000. The Protein Data Bank. Nucl Acid Res 28, 235–242.
Citron, M. 2004a. Beta-secretase inhibition for the treatment of Alzheimer’s disease — promise and challenge. Trends Pharmacol Sci 25, 92–97.
Citron, M. 2004b. Strategies for disease modification in Alzheimer’s disease. Nat Rev Neurosci 5, 677–685.
Coburn, A. 2005. Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer’s disease. US Patent 7714021.
Coburn, C.A., Nantermet, P.G., Rajapakse, H.A., Selnick, H.G., Stauffer, S.R. 2006a. Aminomethyl betasecretase inhibitors for the treatment of Alzheimer’s disease. US Patent 7820674.
Coburn, C.A., Stachel, S.J., Vacca, J.P. 2006b. Nalkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer’s disease. US Patent 20060161020.
Cole, D.C., Stock, J.R., Chopra, R., Cowling, R., Ellingboe, J.W., Fan, K.Y. 2008. Acylguanidine inhibitors of beta-secretase: Optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett 18, 1063–1066.
Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T. 2004. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47, 1739–1749.
Ghosh, A.K., Bilcer, G., Hong, L., Koelsch, G., Tang, J. 2007. Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality. Curr Alzheimer Res 4, 418–422.
Hess, B., Bekker, H., Berendsen, H.J.C., Fraaije, J.G.E.M. 1997. LINCS: A linear constraint solver for molecular simulations. J Comput Chem 18, 1463–1472.
Hess, B., Kutzner, C., Van Der Spoel, D., Lindahl, E. 2008. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4, 435.
Huang, D., Luthi, U., Kolb, P., Cecchini, M., Barberis, A., Caflisch, A. 2006. In silico discovery of betasecretase inhibitors. J Am Chem Soc 128, 5436–5443.
Hussain, I., Powell, D.J., Howlett, D.R., Chapman, G.A., Gilmour, L., Murdock, P.R. 2000. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci 16, 609–619.
James, C., Barrow, K.E., Rittle, L.B. 2007. Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of Alzheimer’s disease. WO/2007/058862. http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007058862&recNum=189&docAn=US2006043536&queryString=(FP/secretase)%2520&maxRec=458.
Kansal, N., Silakari, O., Ravikumar, M. 2010. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. Eur J Med Chem 45, 393–404.
LigPrep. 2011. Version 2.5, Schrödinger, LLC, New York.
Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3–26.
Loving, K., Salam, N., Shermanm, W. 2009. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23, 541–554.
Matera, R. 2009. Design and Synthesis of Novel Non Peptidomimtic Beta-Secretase Inhibitors in the Treatment of Alzheimer’s Disease. PhD Thesis submitted to, Bologna University.
Nantermet, P.G., Holloway, K.M., Moore, K.P., Stauffer, S.R. 2008. Macrocyclic spiropiperidine betasecretase inhibitors for the treatment of Alzheimer’s disease. US Patent 20100029701.
Nantermet, P.G., Rajapakse, H.A., Selnick, H.G., Lindsley, S., Moore, K.P., Stachel, S.J. 2006. Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer’s disease. US Patent 7678783.
Nash, H.M., Tadikonda, P.K., Wang, T. 2008. Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of Alzheimer’s disease. US Patent 7449599.
Petrova, S.S., Solov’ev, A.D. 1985. The origin of the method of steepest descent. Historia Mathematica 24, 361–375.
QikProp. 2011. Version 3.4, Schrödinger, LLC, New York.
Tana, S. 2004. Alzheimer’s disease — opportunities to address pharmaceutical gaps. In: Kaplan, W., Laing, R. (Eds.) Priority Medicines for Europe and the World — A Public Health Approach to Innovation. World Health Organization, Geneva, Switzerland, 3–6.
Vassar, R. 2000. Beta-secretase (BACE) as a drug target for Alzheimer’s disease. Adv Drug Deliv Rev 54, 1589–1602.
Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P. 1999. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741.
Wolfe, M. 2008. Selective amyloid-beta lowering agents. BMC Neurosci 9, S4.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Muthusamy, K., Singh, K.D., Chinnasamy, S. et al. High throughput virtual screening and E-pharmacophore filtering in the discovery of new BACE-1 inhibitors. Interdiscip Sci Comput Life Sci 5, 119–126 (2013). https://doi.org/10.1007/s12539-013-0157-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12539-013-0157-x